Amethyst Radiotherapy UK has announced an impressive 84 per cent growth in the number of patients treated in 2024 compared to 2020 when Amethyst Healthcare acquired the network.
This development includes a 70.1 per cent increase in NHS patients, underscoring Amethyst’s commitment to work in partnership with the health service to deliver the highest quality of cancer care.
Amethyst UK operates two stereotactic ‘centres of excellence’, in London and Sheffield – both are dedicated to delivering its state-of-the-art Gamma Knife treatment.
Gamma Knife is not a knife in the normal sense of the word. Very precisely focused beams of radiation are directed to the treatment area in the brain, optimised to hit only the target while preserving healthy tissue.
It offers a safe and effective treatment for more than 80,000 patients worldwide every year. The treatment procedure is simple and straightforward.
Sophie Ward, Group Chief Marketing Officer, commented: “We are thrilled to see such robust growth in the number of patients we’ve been able to treat over the past four years.
“This is a testament to the work of the entire Amethyst team, which has enabled such a huge number of patients to benefit from our world-leading services.
“With the NHS under such intense pressure, we stand ready to provide further support if necessary in order to drive down waiting times and provide for patients.
“To deliver this growth throughout such a challenging period, including the COVID pandemic, speaks volumes about what Amethyst is capable of providing. We look forward to building on this success, benefiting both NHS and private patients.”
Looking ahead, Amethyst Radiotherapy UK plans to expand its capabilities and enhance its service offerings to meet the growing demand for cancer care.
The company’s vision includes partnerships with NHS trusts and private healthcare providers to ensure patients receive timely and effective treatment.
